LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) provided an update on recent 2012 achievements and anticipated milestones following the closing of its follow-on financing.
Commented John S. Yu, MD, Interim Chief Executive Officer: “We are pleased with our progress in the third quarter of 2012 and year to date. Our fundamentals are strong. This month, we completed a significant underwritten public financing, which provided approximately $19.3 million of cash, net of commissions and expenses, achieving our goal of capitalizing the company with sufficient cash runway to enable us to achieve our near-term objectives.
